Business Context and Reporting Period
This Form 8-K was filed by Onconova Therapeutics, Inc. (Note: The request metadata listed "Traws Pharma, Inc.", but the filing text identifies the registrant as Onconova Therapeutics, Inc.) on May 20, 2021. The report details corporate governance actions taken following a Special Meeting of Stockholders held on April 30, 2021, specifically regarding amendments to the Company's Certificate of Incorporation.
Key Financial Metrics
This filing is a current report regarding corporate structure and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for these metrics.
Material Changes Versus Prior Period
- Reverse Stock Split: The Company effected a one-for-fifteen reverse stock split effective May 20, 2021. This reduced the number of common shares issued and outstanding from approximately 236.714 million to approximately 15.781 million.
- Authorized Shares Reduction: The number of authorized shares of capital stock was decreased from 255,000,000 to 130,000,000. Specifically, authorized common stock was reduced from 250,000,000 to 125,000,000 shares.
- Warrant Adjustments: Outstanding tradable warrants (symbol "ONTXW") were adjusted. Each warrant now entitles the holder to purchase 1/225th of a share at an exercise price of $1,107.00 per share.
- Trading Symbol and CUSIP: The stock continues to trade on the NASDAQ Capital Market under the symbol ONTX, but with a new CUSIP number: 68232V 801.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The document focuses exclusively on the mechanics of the reverse stock split, the reduction of authorized shares, and the administrative adjustments to equity instruments (options, warrants, and convertible preferred stock). Fractional shares resulting from the split were rounded up to a full share for stockholders, while fractional shares from warrant exercises were rounded down.
Important Facts for Investor Verification
- Verify the new share count of approximately 15.781 million shares outstanding.
- Confirm the adjusted exercise price of tradable warrants is $1,107.00 per share.
- Check the new CUSIP number (68232V 801) for accurate trading and settlement.
- Note that the reverse stock split became effective on May 20, 2021, with split-adjusted trading commencing May 21, 2021.
- Review the reduction in authorized shares to 130,000,000 total (125,000,000 common).